Real‐world data on EGFR/ALK gene status and first‐line targeted therapy rate in newly diagnosed advanced non‐small cell lung cancer patients in Northern China: A prospective observational study
Background Tyrosine kinase inhibitors (TKIs) can significantly prolong overall survival for patients with advanced non‐small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR)‐mutation or anaplastic lymphoma kinase (ALK)‐rearrangement. However, the real‐world evaluation statu...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2019-07-01
|
| Series: | Thoracic Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1111/1759-7714.13090 |
| _version_ | 1819066545403330560 |
|---|---|
| author | Hongge Liang Xia Song Yuhui Zhang Shucai Zhang Fang Li Jian Fang Junling Li Li Liang Ligong Nie Kewei Ma Liangming Zhang Xiaohong Wang Junjun Xu Yanxia Wei Jinghui Wang Qi Song Guangming Tian Yuxin Mu Yangchun Gu Lei Yang Ping Sun Wei Zhong Jing Zhao Yan Xu Minjiang Chen Mengzhao Wang |
| author_facet | Hongge Liang Xia Song Yuhui Zhang Shucai Zhang Fang Li Jian Fang Junling Li Li Liang Ligong Nie Kewei Ma Liangming Zhang Xiaohong Wang Junjun Xu Yanxia Wei Jinghui Wang Qi Song Guangming Tian Yuxin Mu Yangchun Gu Lei Yang Ping Sun Wei Zhong Jing Zhao Yan Xu Minjiang Chen Mengzhao Wang |
| author_sort | Hongge Liang |
| collection | DOAJ |
| description | Background Tyrosine kinase inhibitors (TKIs) can significantly prolong overall survival for patients with advanced non‐small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR)‐mutation or anaplastic lymphoma kinase (ALK)‐rearrangement. However, the real‐world evaluation status of ALK/EGFR in China remains unclear. Methods We conducted a prospective study including 1134 patients with cytologically or histologically confirmed advanced NSCLC (stage IIIb–IV) at 12 Chinese hospitals. Results The most common evaluation methods were amplification‐refractory mutation system for EGFR status and immunohistochemistry targeting D5F3 for ALK status. Among patients with non‐squamous, the EGFR mutation rate was 44.1% and the ALK rearrangement rate was 10.0%. Among patients with squamous cell carcinoma, the EGFR mutation rate was 8.3% and the ALK rearrangement rate was 3.7%. Among all patients, gender (HR = 1.7, 95%CI = 1.2–2.4, P = 0.006), smoking history (HR = 1.8, 95%CI = 1.3–2.7, P = 0.001), histology (HR = 5.0, 95%CI = 2.4–10.1, P < 0.001), and brain metastases (HR = 1.5, 95%CI = 1.1–2.2, P = 0.017) were independent predictors of EGFR mutation, while age (HR = 2.6, 95%CI = 1.7–4.1, P < 0.001) was an independent predictor of ALK rearrangement. The median time from tumor diagnosis to EGFR or ALK status confirmation was 7 and 5 days, respectively. Targeted therapy rate was 73.8% in EGFR‐positive patients and 51.4% in ALK‐positive patients. There was a negative correlation between the first‐line targeted therapy rate and the EGFR mutation detection period (r = −0.152, P = 0.02), while no significant correlation among patients with ALK rearrangement (r = −0.179, P = 0.076). Conclusion Squamous NSCLC patients should also be routinely tested to determine their EGFR/ALK statuses. The first‐line targeted therapy rate remains low in Chinese patients with NSCLC. |
| first_indexed | 2024-12-21T16:04:04Z |
| format | Article |
| id | doaj.art-ad60baa3f8544daa82949c57425b382c |
| institution | Directory Open Access Journal |
| issn | 1759-7706 1759-7714 |
| language | English |
| last_indexed | 2024-12-21T16:04:04Z |
| publishDate | 2019-07-01 |
| publisher | Wiley |
| record_format | Article |
| series | Thoracic Cancer |
| spelling | doaj.art-ad60baa3f8544daa82949c57425b382c2022-12-21T18:57:55ZengWileyThoracic Cancer1759-77061759-77142019-07-011071521153210.1111/1759-7714.13090Real‐world data on EGFR/ALK gene status and first‐line targeted therapy rate in newly diagnosed advanced non‐small cell lung cancer patients in Northern China: A prospective observational studyHongge Liang0Xia Song1Yuhui Zhang2Shucai Zhang3Fang Li4Jian Fang5Junling Li6Li Liang7Ligong Nie8Kewei Ma9Liangming Zhang10Xiaohong Wang11Junjun Xu12Yanxia Wei13Jinghui Wang14Qi Song15Guangming Tian16Yuxin Mu17Yangchun Gu18Lei Yang19Ping Sun20Wei Zhong21Jing Zhao22Yan Xu23Minjiang Chen24Mengzhao Wang25Respiratory Medicine Peking Union Medical College Hospital Beijing ChinaRespiratory Medicine Shanxi Provincial Cancer Hospital Taiyuan ChinaRespiratory Medicine Beijing Chaoyang Hospital Beijing ChinaMedical Oncology Beijing Chest Hospital, Capital Medical Hospital Beijing ChinaMedical Oncology Military General Hospital of Beijing Beijing ChinaMedical Oncology Beijing Cancer Hospital Beijing ChinaMedical Oncology Chinese Academy of Medical Sciences Cancer Institute and Hospital Beijing ChinaMedical Oncology Peking University Third Hospital Beijing ChinaRespiratory Medicine Peking University First Hospital Beijing ChinaMedical Oncology Jilin University First Hospital Changchun ChinaMedical Oncology Qindao University Medical College Affiliated Yantai Yuhuangding Hospital Yantai ChinaMedical Oncology Baotou Cancer Hospital Baotou ChinaRespiratory Medicine Shanxi Provincial Cancer Hospital Taiyuan ChinaRespiratory Medicine Beijing Chaoyang Hospital Beijing ChinaMedical Oncology Beijing Chest Hospital, Capital Medical Hospital Beijing ChinaMedical Oncology Military General Hospital of Beijing Beijing ChinaMedical Oncology Beijing Cancer Hospital Beijing ChinaMedical Oncology Chinese Academy of Medical Sciences Cancer Institute and Hospital Beijing ChinaMedical Oncology Peking University Third Hospital Beijing ChinaMedical Oncology Jilin University First Hospital Changchun ChinaMedical Oncology Qindao University Medical College Affiliated Yantai Yuhuangding Hospital Yantai ChinaRespiratory Medicine Peking Union Medical College Hospital Beijing ChinaRespiratory Medicine Peking Union Medical College Hospital Beijing ChinaRespiratory Medicine Peking Union Medical College Hospital Beijing ChinaRespiratory Medicine Peking Union Medical College Hospital Beijing ChinaRespiratory Medicine Peking Union Medical College Hospital Beijing ChinaBackground Tyrosine kinase inhibitors (TKIs) can significantly prolong overall survival for patients with advanced non‐small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR)‐mutation or anaplastic lymphoma kinase (ALK)‐rearrangement. However, the real‐world evaluation status of ALK/EGFR in China remains unclear. Methods We conducted a prospective study including 1134 patients with cytologically or histologically confirmed advanced NSCLC (stage IIIb–IV) at 12 Chinese hospitals. Results The most common evaluation methods were amplification‐refractory mutation system for EGFR status and immunohistochemistry targeting D5F3 for ALK status. Among patients with non‐squamous, the EGFR mutation rate was 44.1% and the ALK rearrangement rate was 10.0%. Among patients with squamous cell carcinoma, the EGFR mutation rate was 8.3% and the ALK rearrangement rate was 3.7%. Among all patients, gender (HR = 1.7, 95%CI = 1.2–2.4, P = 0.006), smoking history (HR = 1.8, 95%CI = 1.3–2.7, P = 0.001), histology (HR = 5.0, 95%CI = 2.4–10.1, P < 0.001), and brain metastases (HR = 1.5, 95%CI = 1.1–2.2, P = 0.017) were independent predictors of EGFR mutation, while age (HR = 2.6, 95%CI = 1.7–4.1, P < 0.001) was an independent predictor of ALK rearrangement. The median time from tumor diagnosis to EGFR or ALK status confirmation was 7 and 5 days, respectively. Targeted therapy rate was 73.8% in EGFR‐positive patients and 51.4% in ALK‐positive patients. There was a negative correlation between the first‐line targeted therapy rate and the EGFR mutation detection period (r = −0.152, P = 0.02), while no significant correlation among patients with ALK rearrangement (r = −0.179, P = 0.076). Conclusion Squamous NSCLC patients should also be routinely tested to determine their EGFR/ALK statuses. The first‐line targeted therapy rate remains low in Chinese patients with NSCLC.https://doi.org/10.1111/1759-7714.13090ALK rearrangementEGFR mutationevaluation statusnon‐small cell lung cancer |
| spellingShingle | Hongge Liang Xia Song Yuhui Zhang Shucai Zhang Fang Li Jian Fang Junling Li Li Liang Ligong Nie Kewei Ma Liangming Zhang Xiaohong Wang Junjun Xu Yanxia Wei Jinghui Wang Qi Song Guangming Tian Yuxin Mu Yangchun Gu Lei Yang Ping Sun Wei Zhong Jing Zhao Yan Xu Minjiang Chen Mengzhao Wang Real‐world data on EGFR/ALK gene status and first‐line targeted therapy rate in newly diagnosed advanced non‐small cell lung cancer patients in Northern China: A prospective observational study Thoracic Cancer ALK rearrangement EGFR mutation evaluation status non‐small cell lung cancer |
| title | Real‐world data on EGFR/ALK gene status and first‐line targeted therapy rate in newly diagnosed advanced non‐small cell lung cancer patients in Northern China: A prospective observational study |
| title_full | Real‐world data on EGFR/ALK gene status and first‐line targeted therapy rate in newly diagnosed advanced non‐small cell lung cancer patients in Northern China: A prospective observational study |
| title_fullStr | Real‐world data on EGFR/ALK gene status and first‐line targeted therapy rate in newly diagnosed advanced non‐small cell lung cancer patients in Northern China: A prospective observational study |
| title_full_unstemmed | Real‐world data on EGFR/ALK gene status and first‐line targeted therapy rate in newly diagnosed advanced non‐small cell lung cancer patients in Northern China: A prospective observational study |
| title_short | Real‐world data on EGFR/ALK gene status and first‐line targeted therapy rate in newly diagnosed advanced non‐small cell lung cancer patients in Northern China: A prospective observational study |
| title_sort | real world data on egfr alk gene status and first line targeted therapy rate in newly diagnosed advanced non small cell lung cancer patients in northern china a prospective observational study |
| topic | ALK rearrangement EGFR mutation evaluation status non‐small cell lung cancer |
| url | https://doi.org/10.1111/1759-7714.13090 |
| work_keys_str_mv | AT honggeliang realworlddataonegfralkgenestatusandfirstlinetargetedtherapyrateinnewlydiagnosedadvancednonsmallcelllungcancerpatientsinnorthernchinaaprospectiveobservationalstudy AT xiasong realworlddataonegfralkgenestatusandfirstlinetargetedtherapyrateinnewlydiagnosedadvancednonsmallcelllungcancerpatientsinnorthernchinaaprospectiveobservationalstudy AT yuhuizhang realworlddataonegfralkgenestatusandfirstlinetargetedtherapyrateinnewlydiagnosedadvancednonsmallcelllungcancerpatientsinnorthernchinaaprospectiveobservationalstudy AT shucaizhang realworlddataonegfralkgenestatusandfirstlinetargetedtherapyrateinnewlydiagnosedadvancednonsmallcelllungcancerpatientsinnorthernchinaaprospectiveobservationalstudy AT fangli realworlddataonegfralkgenestatusandfirstlinetargetedtherapyrateinnewlydiagnosedadvancednonsmallcelllungcancerpatientsinnorthernchinaaprospectiveobservationalstudy AT jianfang realworlddataonegfralkgenestatusandfirstlinetargetedtherapyrateinnewlydiagnosedadvancednonsmallcelllungcancerpatientsinnorthernchinaaprospectiveobservationalstudy AT junlingli realworlddataonegfralkgenestatusandfirstlinetargetedtherapyrateinnewlydiagnosedadvancednonsmallcelllungcancerpatientsinnorthernchinaaprospectiveobservationalstudy AT liliang realworlddataonegfralkgenestatusandfirstlinetargetedtherapyrateinnewlydiagnosedadvancednonsmallcelllungcancerpatientsinnorthernchinaaprospectiveobservationalstudy AT ligongnie realworlddataonegfralkgenestatusandfirstlinetargetedtherapyrateinnewlydiagnosedadvancednonsmallcelllungcancerpatientsinnorthernchinaaprospectiveobservationalstudy AT keweima realworlddataonegfralkgenestatusandfirstlinetargetedtherapyrateinnewlydiagnosedadvancednonsmallcelllungcancerpatientsinnorthernchinaaprospectiveobservationalstudy AT liangmingzhang realworlddataonegfralkgenestatusandfirstlinetargetedtherapyrateinnewlydiagnosedadvancednonsmallcelllungcancerpatientsinnorthernchinaaprospectiveobservationalstudy AT xiaohongwang realworlddataonegfralkgenestatusandfirstlinetargetedtherapyrateinnewlydiagnosedadvancednonsmallcelllungcancerpatientsinnorthernchinaaprospectiveobservationalstudy AT junjunxu realworlddataonegfralkgenestatusandfirstlinetargetedtherapyrateinnewlydiagnosedadvancednonsmallcelllungcancerpatientsinnorthernchinaaprospectiveobservationalstudy AT yanxiawei realworlddataonegfralkgenestatusandfirstlinetargetedtherapyrateinnewlydiagnosedadvancednonsmallcelllungcancerpatientsinnorthernchinaaprospectiveobservationalstudy AT jinghuiwang realworlddataonegfralkgenestatusandfirstlinetargetedtherapyrateinnewlydiagnosedadvancednonsmallcelllungcancerpatientsinnorthernchinaaprospectiveobservationalstudy AT qisong realworlddataonegfralkgenestatusandfirstlinetargetedtherapyrateinnewlydiagnosedadvancednonsmallcelllungcancerpatientsinnorthernchinaaprospectiveobservationalstudy AT guangmingtian realworlddataonegfralkgenestatusandfirstlinetargetedtherapyrateinnewlydiagnosedadvancednonsmallcelllungcancerpatientsinnorthernchinaaprospectiveobservationalstudy AT yuxinmu realworlddataonegfralkgenestatusandfirstlinetargetedtherapyrateinnewlydiagnosedadvancednonsmallcelllungcancerpatientsinnorthernchinaaprospectiveobservationalstudy AT yangchungu realworlddataonegfralkgenestatusandfirstlinetargetedtherapyrateinnewlydiagnosedadvancednonsmallcelllungcancerpatientsinnorthernchinaaprospectiveobservationalstudy AT leiyang realworlddataonegfralkgenestatusandfirstlinetargetedtherapyrateinnewlydiagnosedadvancednonsmallcelllungcancerpatientsinnorthernchinaaprospectiveobservationalstudy AT pingsun realworlddataonegfralkgenestatusandfirstlinetargetedtherapyrateinnewlydiagnosedadvancednonsmallcelllungcancerpatientsinnorthernchinaaprospectiveobservationalstudy AT weizhong realworlddataonegfralkgenestatusandfirstlinetargetedtherapyrateinnewlydiagnosedadvancednonsmallcelllungcancerpatientsinnorthernchinaaprospectiveobservationalstudy AT jingzhao realworlddataonegfralkgenestatusandfirstlinetargetedtherapyrateinnewlydiagnosedadvancednonsmallcelllungcancerpatientsinnorthernchinaaprospectiveobservationalstudy AT yanxu realworlddataonegfralkgenestatusandfirstlinetargetedtherapyrateinnewlydiagnosedadvancednonsmallcelllungcancerpatientsinnorthernchinaaprospectiveobservationalstudy AT minjiangchen realworlddataonegfralkgenestatusandfirstlinetargetedtherapyrateinnewlydiagnosedadvancednonsmallcelllungcancerpatientsinnorthernchinaaprospectiveobservationalstudy AT mengzhaowang realworlddataonegfralkgenestatusandfirstlinetargetedtherapyrateinnewlydiagnosedadvancednonsmallcelllungcancerpatientsinnorthernchinaaprospectiveobservationalstudy |